Department of Nephrology, Urology, and Kidney Transplantation, Coimbra University Hospital Center, Coimbra, Portugal.
Department of Nephrology, Urology, and Kidney Transplantation, Coimbra University Hospital Center, Coimbra, Portugal; Nephrology University Clinic, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Transplant Proc. 2023 Jul-Aug;55(6):1400-1403. doi: 10.1016/j.transproceed.2023.05.006. Epub 2023 Jun 7.
For the average patient with end-stage renal disease, kidney transplantation improves quality of life and prolongs survival compared with patients on the transplant waiting list who remain on dialysis. Patients ≥65 years of age represent an increasing proportion of adults with end-stage renal disease, and kidney transplantation outcomes remain controversial in this population. The aim of this study was to evaluate factors that may increase 1-year mortality after renal transplantation in older recipients.
A retrospective study that included 147 patients (75.5% men) ≥65 years old (mean age 67.5 ± 2 years) who were transplanted between January 2011 and December 2020. The mean follow-up was 52.6 ± 27.2 months.
Rehospitalization (<1 year) occurred in 39.5% of patients. Infectious complications were present in 18.4% of patients. The overall mortality rate was 23.1%, and 1-year mortality was 6.8%. As 1-year mortality predictors, we found a positive correlation with factors related to kidney transplant, such as cold ischemia time (P = .003), increasing donor age (P = .001); and factors related to the receptor such as pretransplantation dialysis modality as peritoneal dialysis (P = .04), cardiovascular disease (P = .004), delayed graft function (P = .002), early cardiovascular complications after kidney transplant (P < .001), and early rehospitalizations (P < .001). No correlation was found between 1-year mortality and age, sex, race, body mass index, and type of kidney transplant.
A more rigorous pretransplant evaluation, focusing on cardiovascular disease and strict exclusion criteria, is recommended for patients ≥65 years old.
对于终末期肾病的普通患者而言,与等待移植且继续接受透析的患者相比,肾移植可改善生活质量并延长生存时间。年龄≥65 岁的患者在终末期肾病患者中所占比例不断增加,而在这一人群中,肾移植的结果仍存在争议。本研究旨在评估可能导致老年受者肾移植后 1 年死亡率增加的因素。
本回顾性研究纳入了 2011 年 1 月至 2020 年 12 月期间接受移植的 147 例(75.5%为男性)年龄≥65 岁(平均年龄 67.5±2 岁)的患者。平均随访时间为 52.6±27.2 个月。
39.5%的患者在 1 年内再次住院。18.4%的患者存在感染性并发症。总死亡率为 23.1%,1 年死亡率为 6.8%。作为 1 年死亡率的预测因素,我们发现与肾移植相关的因素(如冷缺血时间,P=0.003;供者年龄增加,P=0.001)呈正相关;与受体相关的因素(如移植前透析方式为腹膜透析,P=0.04;心血管疾病,P=0.004;延迟肾功能恢复,P=0.002;肾移植后早期心血管并发症,P<0.001;早期再次住院,P<0.001)也与 1 年死亡率相关。1 年死亡率与年龄、性别、种族、体重指数和肾移植类型无关。
建议对年龄≥65 岁的患者进行更严格的移植前评估,重点关注心血管疾病和严格的排除标准。